Celsion Announces FDA Clearance of the OPTIMA Study – A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer

[PR Newswire] – LAWRENCEVILLE, N.J., Feb. 24, 2014 /PRNewswire/ — Celsion Corporation (CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-co more

View todays social media effects on CLSN

View the latest stocks trending across Twitter. Click to view dashboard

See who Celsion is hiring next, click here to view